Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
Cytek Biosciences (Nasdaq: CTKB) has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 5, 2024. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss results, business developments, and outlook. The webcast will be accessible through the Investors section of Cytek's website.
Cytek Biosciences (Nasdaq: CTKB) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato martedì 5 novembre 2024. L'azienda ospiterà una conferenza telefonica e un webcast alle 13:30 ora del Pacifico / 16:30 ora dell'Est nello stesso giorno per discutere i risultati, gli sviluppi aziendali e le prospettive. Il webcast sarà accessibile attraverso la sezione Investitori del sito web di Cytek.
Cytek Biosciences (Nasdaq: CTKB) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el martes 5 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica y un webcast a la 1:30 p.m. hora del Pacífico / 4:30 p.m. hora del Este el mismo día para discutir los resultados, los desarrollos comerciales y las perspectivas. El webcast estará disponible a través de la sección para inversores en el sitio web de Cytek.
Cytek Biosciences (Nasdaq: CTKB)는 2024년 11월 5일 화요일 주식 시장 종료 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 태평양 시간 오후 1시 30분 / 동부 시간 오후 4시 30분에 결과, 비즈니스 개발 및 전망에 대해 논의하는 전화 회의와 웹캐스트를 개최할 예정입니다. 웹캐스트는 Cytek의 웹사이트의 투자자 섹션을 통해 접근할 수 있습니다.
Cytek Biosciences (Nasdaq: CTKB) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la fermeture du marché le mardi 5 novembre 2024. L'entreprise organisera une conférence téléphonique et un webcast à 13h30 heure du Pacifique / 16h30 heure de l'Est le même jour pour discuter des résultats, des évolutions commerciales et des perspectives. Le webcast sera accessible via la section Investisseurs du site web de Cytek.
Cytek Biosciences (Nasdaq: CTKB) hat angekündigt, dass die finanziellen Ergebnisse für das dritte Quartal 2024 nach Marktschluss am Dienstag, den 5. November 2024, veröffentlicht werden. Das Unternehmen wird am selben Tag um 13:30 Uhr Pazifischer Zeit / 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse, Geschäftsentwicklungen und Aussichten zu besprechen. Der Webcast wird über den Investor-Bereich der Cytek-Website zugänglich sein.
- None.
- None.
FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
When will Cytek Biosciences (CTKB) release Q3 2024 earnings?
What time is Cytek Biosciences (CTKB) Q3 2024 earnings call?
Where can I access Cytek Biosciences (CTKB) Q3 2024 earnings webcast?
